Table 2.
Mechanisms, cardiovascular adverse effects, advantages and disadvantages of several medications used in SARS-CoV-2 infection.
| Medication | MOA | Effect on SARS-CoV-2 | CV toxicity | Advantages | Disadvantages | Ref |
|---|---|---|---|---|---|---|
| Remdesivir | RDRP inhibitor | Reduces symptoms in SARS-CoV-2 patients, inhibits SARS-CoV-2 infection in vitro | Unknown | Established safety profile, resistant to nsp14-ExoN | Causes viral resistance, and must be injected | [17], [77] |
| Chloroquine/Hydroxychloroquine | Raises endosomal pH and anti-inflammation | Blocks SARS-CoV-2 from early endosomes to endolysosomes, blocks glycosylation of ACE2 | Myocardial toxicity, QT prolongation, altered cardiac conductivity | High oral bioavailability, concentrates in lungs | concentrates in the liver, spleen and kidney and efficacy has been debated | [17], [79], [80] |
| Nitazoxanide | Blocks pyruvate ferredoxin oxidoreductase in anaerobes | Inhibits growth of SARS-CoV-2 and cytokine production from PMNs and IL-6 production | Unknown | parent drug and metabolite are active, can be given orally | Expensive, and safety profile is less understood | [17] |
| Lopinavir/Ritonavir | Protease inhibitor/CYP450 inhibitor | Shortens median hospital stay in SARS-CoV-2 infected patients | QT interval prolongation, and high degree atrioventricular block | Well studied, oral route | Does not reduce SARS-CoV-2 mortality in recent studies | [78], [84] |
| Ribavirin | RDRP inhibitor | Inhibits in vitro growth of SARS-CoV-2 at high concentrations | Unknown | Low cost and well-studied | worsens in some patients outcomes and efficacy is debated | [17], [76] |
| Convalescent plasma | Performs neutralizing immunoglobulin targeting SARS-CoV-2 | Lowers viral load and lead to quick improvement of symptoms in critically ill COVID-19 patients | Unknown | Immunomodulatory effects: potentially mitigate cytokine storm | Ineffective in MERS-CoV prophylaxis and must be injected | [87] |
| Corticosteroids | Reduces inflammatory mediators | combat the damage from cytokine storm, reducing lung injury | Immunosuppression, cardiovascular and metabolic disorders | Useful in later stages of infection | Must be injected, raises mortality and adverse effect risk if used inappropriately | [5], [78] |
| Ammonium chloride | Raises endosomal pH | Blocks glycosylation of ACE2 receptors and inhibited viral growth in vitro | Ammonia toxicity can lead to bradyarrhythmia | Cheap, few apparent drug interactions | Not well studied and uncommonly used in humans | [17] |
| ACEI/ARB | Reduces Ang II effect and prevents vasoconstriction | Upregulates ACE2 and prevents overproduction of Ang II, reduces cardiac and lung injury | Hypotension | Well studied, low side effect profile, cheap | not directly target virus and ACE2 upregulation provides virus with more sites to attack | [53] |
| Tocilizumab | Inhibits IL-6 receptor | combat the damage from cytokine storm | Hypertension, and increased serumcholesterol | Inhibit IL-6 and mitigate cytokine storm | Expensive and does not target SARS-CoV-2 | [30] |